{"id":"NCT00527605","sponsor":"GlaxoSmithKline","briefTitle":"Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Six-month Parallel-group Study to Assess Efficacy and Safety of Dutasteride 0.5mg Once Daily in Chinese Patients With Benign Prostatic Hyperplasia (BPH), Followed by a 12-month Open-label Treatment Phase","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2007-09-11","resultsPosted":"2010-03-11","lastUpdate":"2012-03-21"},"enrollment":253,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Benign Prostatic Hyperplasia","Prostatic Hyperplasia"],"interventions":[{"type":"DRUG","name":"Dutasteride 0.5mg capsule","otherNames":[]},{"type":"DRUG","name":"Dutasteride matched placebo","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"PLACEBO_COMPARATOR"}],"summary":"This randomized, double-blind, placebo-controlled, six-month parallel-group study assess efficacy and safety of dutasteride 0.5mg once daily in Chinese patients with Benign Prostatic Hyperplasia (BPH) , followed by a 12-month open-label treatment phase","primaryOutcome":{"measure":"Percent Change From Baseline in the Prostate Volume at Month 6","timeFrame":"Baseline and Month 6","effectByArm":[{"arm":"Dutasteride 0.5 mg","deltaMin":-17,"sd":21.41},{"arm":"Placebo","deltaMin":-2.77,"sd":24.96}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"50 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":12,"countries":["China"]},"refs":{"pmids":["27933597","22017520"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":126},"commonTop":["Upper respiratory tract infection","Stomach discomfort","Nasopharyngitis","Back pain","Libido decreased"]}}